Empower India’s R&D with Digital Intelligence
Accelerate generics, biosimilars and specialty-chemical development through unified, science-driven workflows
India’s R&D industry is rapidly evolving, from generics and biosimilars to advanced biologics and specialty chemicals. Whether you are a multinational, CDMO, CRO or home-grown pharma innovator, Revvity Signals brings you a unified digital platform to manage data, streamline workflows and ensure compliance.
With modern, secure, cloud-native tools built for science, you can reduce development timelines, improve collaboration, and stay ahead of regulatory and market demands.
The New R&D Reality
Core Challenges for India’s Pharma & Biotech Leaders
India’s pharma and biotech sectors are transforming rapidly. With AI reshaping scientific workflows, biologics and biosimilars becoming more complex, and data volumes growing exponentially, organizations face a new set of strategic challenges. These pressures demand modern, unified digital environments that ensure speed, scientific rigor, and regulatory confidence.
AI Introduces New Expectations for Data Readiness & Scientific Insight
AI promises faster discovery, predictive modelling, and smarter decision-making only when organizations have the foundation to support it. Commonplace across India are challenges with:
- fragmented, inconsistent data that limits AI accuracy
- disconnected systems that prevent training high-quality models
- lack of structured, FAIR-ready scientific data
- difficulties integrating AI into routine R&D workflows
Digital Transformation Is No Longer Optional
Indian R&D organizations still operate under variable digital‑maturity levels. Many rely on manual workflows, paper-based labs, spreadsheets and disconnected data systems. This environment leads to:
- delays in experiment execution and review
- inconsistent documentation and weak traceability
- rework, duplication or data loss due to manual handoffs
- inefficiency when coordinating across internal teams and external partners
A unified, enterprise-grade digital data backbone can accelerate pace, support compliance and drive global competitiveness.
Read how Natco Pharma Streamlined Development to enable faster regulatory approval
Biosimilars, Biologics & Complex Modalities Drive Massive Data Burden
India’s leadership in biosimilars and biologics brings opportunity, but also complexity. These programs generate vast volumes of multi-step, multi-source data, leading to challenges such as:
- managing analytical, process, and characterization data from multiple platforms
- ensuring comparability across batches and studies
- maintaining watertight traceability for regulatory submissions
- coordinating cross-functional teams across biology, analytics, formulation, and QA
Without digital structure, biologics and biosimilar programs face slower development cycles, higher risk of inconsistencies, and mounting regulatory scrutiny.
Transform R&D, Stay Ahead in India’s Pharma Innovation
India’s pharma and biotech sector faces growing complexity and regulatory demands. Revvity Signals provides AI-enhanced unified, science-driven digital solutions to accelerate development, enhance collaboration, ensure compliance, and turn data into actionable insights, helping Indian innovators modernize R&D and stay competitive.
